2 December 2022
Latham & Watkins Advises on Intellia Therapeutics’ Public Offering of Common Stock
Advising firms
Deal team
5 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Nathan Ajiashvili Lead | Latham & Watkins LLP | Partner | capital markets | Not stated |
| Peter Handrinos Lead | Latham & Watkins LLP | Partner | capital markets | Not stated |
| Sandy Kugbei | Latham & Watkins LLP | Associate | capital markets | Not stated |
| Egzon Sulejmani | Latham & Watkins LLP | Associate | capital markets | Not stated |
| James Sullivan | Latham & Watkins LLP | Associate | capital markets | Not stated |
2 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 300m (US$300 million)
- What the figure measures
- Issue size
- Client
- Not stated
- Counterparties
- Intellia Therapeutics, Inc. (Issuer)
Goldman Sachs & Co. LLC (Underwriters)